MERCURIUS™
DRUG-seq
- RNA extraction-free
- 3' mRNA protocol
- Unbiased transcriptome profiling
- Ideal for large-scale compound screening
- Turnaround time: from 2 weeks
We offer a variety of scalable RNA-seq library preparation, sequencing and analysis services that combine full-transcriptome coverage with unmatched cost-efficiency and the shortest turnaround times on the market.
Whether you are looking to generate and analyze data from tens to thousands of samples, our next-generation RNA-seq technologies are designed to fit your research needs and your timeline.
At Alithea Genomics, we specialize in both bulk and single-cell transcriptomics, offering scalable, high-quality RNA sequencing solutions for a wide range of research needs.
Ready to get started? Tell us about your project, and we will provide a personalized quote based on your specific needs and research goals.
Unlock deeper insights from your RNA-seq data with our tailored data analysis services.
Our preliminary data analysis can be accompanied by publication-ready visualizations such as volcano plots, clustered heatmaps, and our signature barplot wheels.
The DRUG-seq platform enabled us to systematically profile compound-induced transcriptional responses at scale, generating a rich dataset that helped prioritize testable hypotheses. The team at Alithea provided outstanding technical guidance throughout, including support in developing a customized analysis pipeline tailored to our needs. The turnaround time was fast, the process seamless, and the collaboration highly productive. We would be glad to work together again.
Mikołaj Słabicki, Ph.D. Principal Investigator at the MGH Krantz Family Center for Cancer Research. Assistant Professor of Medicine at Harvard Medical School. Affiliate Faculty Member at the Broad Institute of MIT and Harvard
DRUG-seq has completely transformed how I approach and think about transcriptomic screening. It's fast, scalable, and incredibly cost-effective—perfect for profiling hundreds of compounds in parallel. In my experience, it’s one of the most powerful tools for uncovering mechanisms of action and capturing transcriptional signatures at scale. I've used DRUG-seq to profile different cells treated under time points, dose responses, combination treatments, and a variety of complex cellular models, from cardiomyocytes to organoids—and it consistently delivers high-quality, actionable data. The ability to pool samples early without compromising data quality truly makes it a game-changer.
Andrea Hadjikyriacou, Ph.D. Principal Scientist I, Novartis Biomedical Research
BRB-seq was a great way for us to multiplex large numbers of RNA samples for sequencing. We wanted a gene expression curve with a tight temporal resolution, thus, many time points for several conditions. We are very happy with the quality of the results and with the cost benefit.
Dr. Nuno Miguel Luis CNRS Researcher
BRB-seq has proven to be an excellent method for multiplexing a large array of RNA samples for sequencing. Our team sought to generate gene expression profiles to enable our research on possible neurodegeneration therapeutic targets, requiring multiple samples for various experimental conditions. The outcomes have exceeded our expectations in terms of both result quality and cost-effectiveness, leaving us thoroughly satisfied and impressed.
Dr. Emmanouil Metzakopian VP of Research and Development, bit.bio
Check out our blog posts for detailed insights into our services, or read our overview to get the big picture. Still unsure?
Try our Service Selection Tool to find the best fit for your project.
21 Aug 2024
Katarina Pinjusic, Giovanna Ambrosini, Joao Lourenco, Nadine Fournier, Christian Iseli, Nicolas Guex, Olga Egorova, Sina Nassiri and Daniel B. Constam. Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING. Front. Immunol., 2024 Sec. Cancer Immunity and Immunotherapy. Volume 14 - 2023.
Immunology
21 Aug 2024
Radiana Ferrero, Pernille Yde Rainer, Marie Rumpler, Julie Russeil, Magda Zachara, Joern Pezoldt, Guido van Mierlo, Vincent Gardeux, Wouter Saelens, Daniel Alpern, Lucie Favre, Nathalie Vionnet, Styliani Mantziari, Tobias Zingg, Nelly Pitteloud, Michel Suter, Maurice Matter, Kai-Uwe Schlaudraff, Carles Canto, and Bart Deplancke. A human omentum-specific mesothelial-like stromal population inhibits adipogenesis through IGFBP2 secretion. Cell Metabolism 36, 1566–1585 (2024).
Metabolism
19 Aug 2024
Stéphanie Boder‐Pasche, Mustafa Demir, Sarah Heub, Manon Garzuel, Réal Ischer, Daniel Migliozzi, Siegfried Graf, Noa Schmid, H. Baris Atakan, Daria Gudkova, Daniel Alpern, Riccardo Dainese, Bart Deplancke, Gilles Weder. Multi‐well plate lid for single‐step pooling of 96 samples for high‐throughput barcode‐based sequencing. Biomedical Microdevices (2024) 26:18.
Biotechnology